You are here

Home » Content

YAŞ VE HASTALIK SÜRESİ ASTIMLI HASTALARDA TEDAVİYE CEVABI ETKİLER Mİ ?

Do Age and Disease Duration Influence Response to the Treatment in Patients with Asthma?

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: We prospectively 'nvest'gated the correlation between response to the treatment and age and d'sease duration 'n asthmat'c patents with pred'cted FEV1 of 50-80 %, according to changes 'n FEV1 parameter. Material and Methods: E'ghty patents completed the study. All patents regularly utilized 800¬2000 mcg/day inhaled Budeson'de and 100 mcg/day inhaled Salmeterol for three months. The patients' response rate to the treatment was calculated by comparing their initial and final FEV1 values. The statistical correlation between these response rates and patients' age [18-40 years of age (n:25); 41-60 years of age (n:37) and older than 60 years of age (n:18)] and d'sease duration [1-5 years (n:20); 6-10 years (n:18); 11-15 years (n:15); 16-20 years (n:14); longer than 20 years (n:13)] was investigated in a stepwise manner. Results: By evaluation of final FEV1 values and response rates to the treatment found by the difference between initial and final FEV1 values, no difference could be detected between 18-40 years of age and 41-60 years of age groups (p>0.05), but the values in both groups were found to be better than the older than 60 years of age group (p<0.05). Five groups, divided according to the d'sease duration, had the same response rate to the treatment (p>0.05); in comparison of the final FEV1 values, the first group was found to be better than the fifth group (p<0.05). In conclusion, response to the treatment of asthmatic patients older than 60 years of age and with longer than 20 years of disease duration was found to be comparably limited than the patients who were younger and having a disease duration of 1-5 years. Conclusion: We think that in the treatment of such patients, higher doses of inhaled drugs and/or therapeutic combinations including increased number of drugs should be preferred.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Çalışmamızda FEV1 değerleri öngörülenin %50-80'i arasında olan astımlı hastaların FEV1 parametresinde meydana gelen değişik/iğe göre tedaviye verdik/eri cevabın yaş ve hastalık süreler' i/e olan ilişkisini prospektif olarak araştırdık Materyal-Metot: Çalışmayı 80 hasta tamamladı. Tüm hastalar üç ay boyunca düzeni' olarak inha/e 800-2000 mcg/gün Budesonide ve 100mcg/gün Salmeterol kullandılar. Hastaların çalışmanın başındaki ve sonundaki FEV1 değer/erinin karşı/aştırı/masıy/a astım tedavisinden ne oranda fayda gördükler' hesaplandı. Daha sonra bu düzelme oranları i/e basamak/ı olarak hastaların yaşı [18-40 yaş (n:25); 41-60 yaş (n:37) ve 60 yaşın üzer'ndek'ler (n:18)] ve hastalık süreler' [1-5 yıl (n:20); 6¬10 yıl (n:18); 11-15 yıl (n:15); 16-20 yıl (n:14); 20 yılın üstü (n:13)] arasındaki 'statistiki 1/işki araştırıldı. Bulgular: Yaşa göre ayrılan üç grubun son FEV1 değerler' karşılaştırmalarında ve i/k ve son FEV1 değerler' arasındaki farkın bulunmasıyla hesaplanan tedav'den fayda görme oranları bakımından 18¬40 ve 41-60 yaş grupları arasında fark saptanmazken (p>0.05), her iki gruptaki değerler de 60 yaş üstü gruptan daha 'y' bulundu (p<0.05). Hastalık süre/erine göre oluşturulan beş grup 'se tedav'den aynı oranda fayda görürken (p>0.05); son FEV11er'n'n karşılaştırılmasında birinci grup, beşinci gruba göre daha iyi bulundu (p<0.05). Sonuç olarak; 60 yaşın üzerindeki ve hastalık süresi 20 yıldan fazla olan astımlı hastaların tedaviye verdik/eri cevap daha genç ve 1-5 yıldır astımlı olan hastalara kıyasla sınırlı bulunmuştur. Sonuç: B'z bu t'p hastaların tedavi/erinde daha yüksek inha/e i/aç dozlarının ve/veya daha fazla sayıda i/aç 'çeren tedavi kombinasyon/arının tercih edilmesi gerektiğini düşünüyoruz.
FULL TEXT (PDF): 
PDF icon arastirmax-yas-hastalik-suresi-astimli-hastalarda-tedaviye-cevabi-etkiler-mi.pdf
  • 4
343-346
  • Turkish

REFERENCES

References: 

1. Salome CM, Peat JK, Britton WJ, Woolcock AJ. Bronchial hyperresponsiveness in two populations of Australian school children. Relation to respiratory symptoms and diagnosis. Clin Allergy 1987; 17:271-81.
2. European Community Respiratory Health Survey. The prevalence of respiratory symptoms in the European Community. Eur Rspir J 1996;9:687-95.
3. Peat JK, Haby M, Spikjer J, Berry G, Woolcock A. Has the prevalence of adult asthma increased? Results from two population studies conducted at a nine year interval in Busselton, Western Australia. Br Med J 1992;305:1326-9.
4. Fish JE, Peters SP. Asthma: Clinical presentation and management. In: Fishman AP ed. Fishman's Pulmonary Diseases and Disorders. 3rd. Ed.
New York: McGraw-Hill 1998:757-76.
5. Barnes PJ, Holgate ST, Laitinen LA, et al. Asthma mechanisms, determinants of severity and treatment. J Allergy Clin Immunol
1996;98:S1-160.
6. Sobonya RE. Quantitative structural alterations in long-standing allergic asthma. Am Rev Respir Dis 1984;130:289-92.
7. O'Byrne PM, Postma DS. The many faces of airway inflamation. Asthna and COPD. Am J Respir Crit Care Med 1999;159:S41-63.
8. Griffin E, Hkansson L, Formgren H. Blood eosinophil number and activity in relation to lung function in patients with asthma and eosinophilia. J Allergy Clin Immunol 1991;87:548-57.
9. Moreno RH, Hogg JC, Pare PD. Mechanics of airway narrowing. Am Rev
Respir Dis 1986;133:1171-80.
10. Ulrick CS, Frederiksen J. Mortality and markers of risk of asthma death among 1075 outpatients with asthma. Chest 1995;108:10-5.
11. Louıs R, Lau LCK, Bron AO, Roldaaam AC, Radermecker M. The relationship between airways inflamation and asthma severity. Am J
Respir Crit Care Med 2000,161:9-16.
12. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am
Rev Respir Dis 1985;131:599-606.
13. Braman SS, Kaemmerlen JT, Davis SM. Asthma in elderly. A comparison between patients recently acquired and long standing disease. Am Rev
Respir Dis 1991;143:336-40.
14. Renwick DS, Connoly MJ. Improving outcomes in elderly patientswith asthma. Drugs Aging 1999;14:1-9.
15. Panhyusen CIM, Vomk JM, Koeter GH. Adult patients may outgrow their
asthma. Am J Respir Crit Care Med 1997;197:1267-72.
16. Postma DS, Lebowitz MD. Persistence and new onset of asthma and chronic bronchitis evaluated longitudinally in a community population sample of adults. Arch Intern Med 1995;155:1393-9..
17. Ulrick CS, Backer V, Dirksen A. A ten year follow-up of 180 adults with bronchial asthma: factors important in the decline in lung function.
Thorax 1992;47:14-8.
18. Bradding PA, Redington E, Holgate ST. Airway wall remodelling in the pathogenesis of asthma: cytokine expression in the airways. In: Stewart GA ed. Airway Wall Remodelling in Asthma. Philadelphia: CRC Press 1997:29-63.
19. Woolcock AJ. Assessment of bronchial hyperresponsiveness as a guide to prognosis and therapy in asthma. Med Clin North Am 1990;74:753-
65.
20. Pattemore PK, Holgate ST. Bronchial hyperresponsiveness and its relation to asthma in childhood. Clin Exp Allergy 1993;23:886-900.
21. Dunnill MS. The pathology ofasthma, with special reference to changes in the bronchial mucosa. J Clin Pathol 1960;13:27-33.
22. Connolly CK, Chan NS, Prescott RJ. The relationship between age and duration of asthma and presence of persistent obstruction in asthma.
Postgrad Med J 1988:64:422-5

Thank you for copying data from http://www.arastirmax.com